Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Income Statement [Abstract]
Product Revenues – net of Discounts and Rebates		$ 437,602	$ 135,293	$ 702,086	$ 365,939
Cost of Revenues		537,690	111,687	661,013	266,688
Gross (Loss) Profit		(100,088)	23,606	41,073	99,251
Research Revenues		90,960	12,818	390,630	43,177
Net (Loss) Revenue		(9,128)	36,424	431,703	142,428
Operating Expenses:
Research and Development		809,777	940,063	1,467,283	4,372,571
General and Administrative Expenses		1,506,620	1,215,053	4,805,648	3,419,747
Total Operating Expenses		2,316,397	2,155,116	6,272,931	7,792,318
Loss from Operations		(2,325,525)	(2,118,692)	(5,841,228)	(7,649,890)
Interest Expense		(1,708)	(1,467)	(4,719)	(6,490)
Change in Fair Value of Derivative Liabilities		(21,103)	(56,712)	(156,445)	1,683,034
Other Income, net		31,550	16,623	74,938	67,358
Total Interest and Other Income (Expense), net		8,739	(41,556)	(86,226)	1,743,902
Loss from Operations before Provision for Income Taxes		(2,316,786)	(2,160,248)	(5,927,454)	(5,905,988)
Provision for Income Taxes (Note 9)		250	250	1,813	751
Net Loss including Noncontrolling Interest		(2,317,036)	(2,160,498)	(5,929,267)	(5,906,739)
Net Loss – Noncontrolling Interest		(712)	(713)	(2,668)	(4,669)
Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc.		(2,316,324)	(2,159,785)	(5,926,599)	(5,902,070)
Comprehensive Loss:
Net Loss		(2,317,036)	(2,160,498)	(5,929,267)	(5,906,739)
Unrealized Foreign Currency Translation Gain		1,230	4,403	8,568	3,646
Total Comprehensive Loss		(2,315,806)	(2,156,095)	(5,920,699)	(5,903,093)
Net Loss – Noncontrolling Interest		(712)	(713)	(2,668)	(4,669)
Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc.		(2,315,094)	(2,155,382)	(5,918,031)	(5,898,424)
Cumulative Dividends on Series A Preferred Stock		(128,097)	(116,571)	(372,960)	(352,333)
Net Loss - attributed to common stockholders		$ (2,443,191)	$ (2,271,953)	$ (6,290,991)	$ (6,250,757)
Net Loss per Common Share:
Basic (in Dollars per share)		$ (0.66)	$ (4.65)	$ (2.92)	$ (21.74)
Diluted (in Dollars per share)		$ (0.66)	$ (2.92)	$ (4.65)	$ (21.74)
Weighted Average Number of Common Shares Outstanding(1)
Basic (in Shares)	[1]	3,675,407	488,654	2,152,682	287,529
Diluted (in Shares)	[1]	3,675,407	2,152,682	488,654	287,529

[1] Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.